A Gene-Therapy Pioneer Just Filed For Chapter 11 Bankruptcy—Now Eli Lilly Wants Its Tech

Sangamo Therapeutics ran out of cash. Eli Lilly and Astellas want the science it spent decades building.

View Post on Scour ↗

More from Inc. on Scour.